[go: up one dir, main page]

FR3113249B1 - PRODUCT FOR THE NASAL TREATMENT OF VIRAL DISEASES - Google Patents

PRODUCT FOR THE NASAL TREATMENT OF VIRAL DISEASES Download PDF

Info

Publication number
FR3113249B1
FR3113249B1 FR2010995A FR2010995A FR3113249B1 FR 3113249 B1 FR3113249 B1 FR 3113249B1 FR 2010995 A FR2010995 A FR 2010995A FR 2010995 A FR2010995 A FR 2010995A FR 3113249 B1 FR3113249 B1 FR 3113249B1
Authority
FR
France
Prior art keywords
product
viral diseases
nasal treatment
nasal
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2010995A
Other languages
French (fr)
Other versions
FR3113249A1 (en
Inventor
Stéphanie Audran
Daniel Greff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmosoft Fr
Original Assignee
Biopass SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopass SA filed Critical Biopass SA
Priority to CN202180067905.9A priority Critical patent/CN116249515A/en
Priority to CA3188053A priority patent/CA3188053A1/en
Priority to PCT/EP2021/071696 priority patent/WO2022029140A1/en
Priority to EP21755445.0A priority patent/EP4192424A1/en
Priority to US18/040,468 priority patent/US20230330013A1/en
Publication of FR3113249A1 publication Critical patent/FR3113249A1/en
Application granted granted Critical
Publication of FR3113249B1 publication Critical patent/FR3113249B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PRODUIT POUR LE TRAITEMENT PAR VOIE NASALE DE MALADIES VIRALES L’invention concerne un produit pour le traitement par voie nasale de maladies virales, comme le COVID-19. Le produit comprend un hydrogel à base de glycérol et d’un carbomère.PRODUCT FOR THE NASAL TREATMENT OF VIRAL DISEASES The invention relates to a product for the nasal treatment of viral diseases, such as COVID-19. The product includes a hydrogel based on glycerol and a carbomer.

FR2010995A 2020-08-04 2020-10-27 PRODUCT FOR THE NASAL TREATMENT OF VIRAL DISEASES Active FR3113249B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202180067905.9A CN116249515A (en) 2020-08-04 2021-08-03 Hydrogel containing glycerol and carbomer for the treatment of respiratory symptoms of COVID-19 disease by nasal route
CA3188053A CA3188053A1 (en) 2020-08-04 2021-08-03 Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route
PCT/EP2021/071696 WO2022029140A1 (en) 2020-08-04 2021-08-03 Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route
EP21755445.0A EP4192424A1 (en) 2020-08-04 2021-08-03 Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route
US18/040,468 US20230330013A1 (en) 2020-08-04 2021-08-03 Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2008276A FR3113237B1 (en) 2020-08-04 2020-08-04 PRODUCT FOR THE TREATMENT OF VIRAL DISEASES BY NASAL WAY
FR2008276 2020-08-04

Publications (2)

Publication Number Publication Date
FR3113249A1 FR3113249A1 (en) 2022-02-11
FR3113249B1 true FR3113249B1 (en) 2024-01-19

Family

ID=73038196

Family Applications (2)

Application Number Title Priority Date Filing Date
FR2008276A Active FR3113237B1 (en) 2020-08-04 2020-08-04 PRODUCT FOR THE TREATMENT OF VIRAL DISEASES BY NASAL WAY
FR2010995A Active FR3113249B1 (en) 2020-08-04 2020-10-27 PRODUCT FOR THE NASAL TREATMENT OF VIRAL DISEASES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR2008276A Active FR3113237B1 (en) 2020-08-04 2020-08-04 PRODUCT FOR THE TREATMENT OF VIRAL DISEASES BY NASAL WAY

Country Status (1)

Country Link
FR (2) FR3113237B1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
FR2973701B1 (en) * 2011-04-06 2013-10-04 Biopass S A COMPOSITION FOR TOPICAL APPLICATION
US10660914B2 (en) 2015-07-14 2020-05-26 Marinomed Biotech Ag Stuffy nose deblocking composition having antiviral activity
CN106511321B (en) * 2016-12-20 2019-03-29 四川省中医药科学院 Composition and drug with anti-inflammatory/antivirus action
CN110840826A (en) * 2019-11-19 2020-02-28 长春呈实健康实业有限公司 Nose blocking agent and preparation method thereof
CN111437270A (en) * 2020-04-24 2020-07-24 瑞希(重庆)生物科技有限公司 Carrageenan nasal in-situ gel spray and preparation method thereof
CN111544556A (en) * 2020-05-07 2020-08-18 中国人民解放军军事科学院军事医学研究院 A Chinese medicinal composition for treating viral common cold and viral pneumonia, and its administration method and preparation method
CN111773150A (en) * 2020-06-22 2020-10-16 复旦大学 A kind of anti-COVID-19 hand-free gel and preparation method thereof

Also Published As

Publication number Publication date
FR3113249A1 (en) 2022-02-11
FR3113237B1 (en) 2023-06-09
FR3113237A1 (en) 2022-02-11

Similar Documents

Publication Publication Date Title
HN2005000508A (en) PROCESSES FOR THE PREPARATION OF 2- (2,6-DIXOPIPERIDIN-3-IL) -1-SUBSTITUTED OXOISOINDOLINES
CR20220626A (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
MX2021010701A (en) Compounds, compositions, and methods for the treatment of disease.
CR20220470A (en) TETRALINE AND TETRAHYDROQUINOLINE COMPOUNDS AS HIF-2ALPH INHIBITORS
PH12021551409A1 (en) Kif18a inhibitors
MX2021007104A (en) Kif18a inhibitors.
MA49809A1 (en) Compounds used as kinase inhibitors
MA43169B1 (en) Heterocyclic compounds as pi3k-gamma inhibitors
WO2023288017A3 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
MA41596B1 (en) Anti-tau antibodies and their uses
WO2021092145A8 (en) Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
SA521430793B1 (en) Anti-sema3a antibodies and their uses for treating eye or ocular diseases
MA53268B1 (en) MINI-GDE FOR THE TREATMENT OF TYPE III GLYCOGEN STORAGE DISEASES
SA522431748B1 (en) Methods for Production of Human Recombinant Arginase 1 and Uses Thereof
MX2023012672A (en) New stable anti-vista antibody.
MX2023014629A (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-qui nazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide.
WO2022169755A8 (en) Sulfonamide substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereof
WO2021023069A8 (en) Application of tpk as a target in alzheimer's disease
FR3113249B1 (en) PRODUCT FOR THE NASAL TREATMENT OF VIRAL DISEASES
MX2021008507A (en) Lilrb3-binding molecules and uses therefor.
WO2020185041A3 (en) Hydrogel including serotonin-modified hyaluronic acid and use thereof
MX2021008865A (en) Methods of treating disease with magl inhibitors.
WO2024023262A3 (en) Nucleic acid compounds
CR20240265A (en) Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
MX2025013683A (en) Small molecule modulators of il-17a, methods of making and methods of using thereof

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220211

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

RM Correction of a material error

Effective date: 20240318

TP Transmission of property

Owner name: COSMOSOFT, FR

Effective date: 20240318

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6